Kate Harrop

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Nancy Whiting, R. Advani, A. Younes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

N. Munshi, R. Sobecks, J. Drachman, 2010, Haematologica.

A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study.

R. Advani, A. Younes, J. Drachman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma.

N. Munshi, J. Drachman, J. Berenson, 2005 .

Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.

N. Munshi, J. Drachman, J. Berenson, 2006 .

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

N. Munshi, R. Sobecks, J. Drachman, 2010, Haematologica.